VEGF
NICE rejects Lucentis for diabetic oedema
March 4, 2011Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab
NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
